

# Gabriel Herrero-Beaumont

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3947812/publications.pdf>

Version: 2024-02-01

179  
papers

11,978  
citations

46918

47  
h-index

28224

105  
g-index

184  
all docs

184  
docs citations

184  
times ranked

10454  
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 1145-1155.	0.5	1,661
2	EULAR evidence based recommendations for the management of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 377-388.	0.5	738
3	EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 669-681.	0.5	704
4	EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 483-489.	0.5	499
5	EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 936-944.	0.5	458
6	An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 337-350.	1.6	392
7	Glucosamine inhibits IL-1 $\beta$ -induced NF $\kappa$ B activation in human osteoarthritic chondrocytes. <i>Osteoarthritis and Cartilage</i> , 2003, 11, 290-298.	0.6	341
8	2018 update of the EULAR recommendations for the management of hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 16-24.	0.5	273
9	Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. <i>Arthritis and Rheumatism</i> , 2007, 56, 555-567.	6.7	248
10	Osteoarthritis associated with estrogen deficiency. <i>Arthritis Research and Therapy</i> , 2009, 11, 241.	1.6	236
11	Subchondral bone as a key target for osteoarthritis treatment. <i>Biochemical Pharmacology</i> , 2012, 83, 315-323.	2.0	220
12	Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 3928-3939.	6.7	194
13	Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 759-766.	0.5	190
14	TLR4 signalling in osteoarthritis – finding targets for candidate DMOADs. <i>Nature Reviews Rheumatology</i> , 2015, 11, 159-170.	3.5	188
15	Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis. <i>Arthritis Research and Therapy</i> , 2010, 12, R152.	1.6	180
16	A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1957-1962.	0.5	159
17	Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?. <i>Drugs and Aging</i> , 2019, 36, 15-24.	1.3	146
18	High-resolution MRI detects cartilage swelling at the early stages of experimental osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2001, 9, 463-472.	0.6	141

#	ARTICLE	IF	CITATIONS
19	A Sonographic Enthesitic Index of lower limbs is a valuable tool in the assessment of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1015-1019.	0.5	140
20	Primary Osteoarthritis No Longer Primary: Three Subsets with Distinct Etiological, Clinical, and Therapeutic Characteristics. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 39, 71-80.	1.6	130
21	Histopathological correlation of cartilage swelling detected by magnetic resonance imaging in early experimental osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2004, 12, 878-886.	0.6	120
22	Bone mineral measurements of subchondral and trabecular bone in healthy and osteoporotic rabbits. <i>Skeletal Radiology</i> , 2006, 35, 34-41.	1.2	118
23	Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2004, 12, 263-268.	0.6	117
24	Why we should definitely include intra-articular hyaluronic acid as a therapeutic option in the management of knee osteoarthritis: Results of an extensive critical literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 563-572.	1.6	110
25	Type 2 diabetes mellitus and osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 9-19.	1.6	110
26	Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. <i>Osteoarthritis and Cartilage</i> , 2007, 15, 69-77.	0.6	102
27	Characterization of a new experimental model of osteoporosis in rabbits. <i>Journal of Bone and Mineral Metabolism</i> , 2008, 26, 53-59.	1.3	99
28	Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. <i>Osteoarthritis and Cartilage</i> , 2011, 19, 1228-1236.	0.6	98
29	Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. <i>Clinical Therapeutics</i> , 2004, 26, 245-256.	1.1	97
30	Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice. <i>Arthritis Care and Research</i> , 2017, 69, 1287-1296.	1.5	95
31	Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Arthritis and Rheumatology</i> , 2017, 69, 77-85.	2.9	94
32	A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 64-69.	0.5	90
33	Lipid Transport and Metabolism in Healthy and Osteoarthritic Cartilage. <i>International Journal of Molecular Sciences</i> , 2013, 14, 20793-20808.	1.8	89
34	Osteoarthritis: a progressive disease with changing phenotypes. <i>Rheumatology</i> , 2014, 53, 1-3.	0.9	87
35	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis. <i>Drugs and Aging</i> , 2015, 32, 179-187.	1.3	82
36	The Increase in O-Linked N-Acetylglucosamine Protein Modification Stimulates Chondrogenic Differentiation Both in Vitro and in Vivo. <i>Journal of Biological Chemistry</i> , 2012, 287, 33615-33628.	1.6	80

#	ARTICLE	IF	CITATIONS
37	Targeting chronic innate inflammatory pathways, the main road to prevention of osteoarthritis progression. <i>Biochemical Pharmacology</i> , 2019, 165, 24-32.	2.0	72
38	Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 998-1005.	0.5	70
39	Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2005, 13, 13-19.	0.6	62
40	Mecanismo de acción de abatacept: concordancia con su perfil clínico. <i>Reumatología Clínica</i> , 2012, 8, 78-83.	0.2	62
41	Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. <i>Agents and Actions</i> , 1994, 41, 171-178.	0.7	61
42	Characterization of multinucleated giant cells in synovium and subchondral bone in knee osteoarthritis and rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 226.	0.8	61
43	Ultrasonographic assessment of Baker's cysts after intra-articular corticosteroid injection in knee osteoarthritis. <i>Journal of Clinical Ultrasound</i> , 2006, 34, 113-117.	0.4	55
44	Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors. <i>Arthritis and Rheumatism</i> , 2009, 60, 2558-2564.	6.7	55
45	Citrullination enhances the pro-inflammatory response to fibrin in rheumatoid arthritis synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1400-1406.	0.5	52
46	Analysis of TNFAIP3, a feedback inhibitor of nuclear factor- $\kappa$ B and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. <i>Arthritis Research and Therapy</i> , 2009, 11, R42.	1.6	51
47	Clinical settings in knee osteoarthritis: Pathophysiology guides treatment. <i>Maturitas</i> , 2017, 96, 54-57.	1.0	51
48	SDF-1 signaling: a promising target in rheumatic diseases. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1077-1087.	1.5	50
49	Mediators and Patterns of Muscle Loss in Chronic Systemic Inflammation. <i>Frontiers in Physiology</i> , 2018, 9, 409.	1.3	50
50	Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 297, H268-H276.	1.5	49
51	RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, R149.	1.6	49
52	Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. <i>British Journal of Pharmacology</i> , 2008, 154, 843-851.	2.7	47
53	Bone mineral density and joint cartilage: four clinical settings of a complex relationship in osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1523-1525.	0.5	47
54	Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. <i>Osteoarthritis and Cartilage</i> , 2015, 23, 2086-2093.	0.6	47

#	ARTICLE	IF	CITATIONS
55	<sc>PTH</sc> [1â€³4] enhances bone response around titanium implants in a rabbit model of osteoporosis. <i>Clinical Oral Implants Research</i> , 2013, 24, 1027-1034.	1.9	46
56	A fibrin based model for rheumatoid synovitis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 1135-1138.	0.5	45
57	Ectopic calcification among families in the Azores: Clinical and radiologic manifestations in families with diffuse idiopathic skeletal hyperostosis and chondrocalcinosis. <i>Arthritis and Rheumatism</i> , 2006, 54, 1340-1349.	6.7	44
58	Increased synovial lipodystrophy induced by high fat diet aggravates synovitis in experimental osteoarthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 264.	1.6	44
59	Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2008, 16, 1484-1493.	0.6	43
60	Commentary: osteoarthritis of the knee and glucosamine. <i>Osteoarthritis and Cartilage</i> , 2006, 14, 963-966.	0.6	42
61	Nonsteroidal antiinflammatory drugs and prostaglandin E<sub>2</sub> modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 478-488.	6.7	42
62	EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1Î in synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1197-1204.	0.5	40
63	Genetic variation in the nuclear factor ÎB pathway in relation to susceptibility to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 579-583.	0.5	40
64	Efficacy and safety of a selective estrogen receptor Î2 agonist, ERÎ41, in patients with rheumatoid arthritis: A 12â€week, randomized, placeboâ€controlled, phase II study. <i>Arthritis Care and Research</i> , 2010, 62, 1588-1593.	1.5	40
65	An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1745-1756.	0.9	39
66	Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis. <i>British Journal of Pharmacology</i> , 2017, 174, 3018-3031.	2.7	38
67	6â€Shogaol inhibits chondrocytesâ€™ innate immune responses and cathepsinâ€K activity. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 256-266.	1.5	37
68	Osteoporotic OA: a reasonable target for bone-acting agents. <i>Nature Reviews Rheumatology</i> , 2013, 9, 448-450.	3.5	34
69	Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1989380.	1.2	34
70	Modulation of cell recruitment by anti-inflammatory agents in antigen-induced arthritis. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 1027-1030.	0.5	32
71	Diacerein has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblastâ€comparison to its effects on osteoarthritic chondrocytes. <i>Rheumatology</i> , 2008, 47, 627-633.	0.9	32
72	Differential effects of the antioxidant n-acetylcysteine on the production of catabolic mediators in IL-1Î2-stimulated human osteoarthritic synoviocytes and chondrocytes. <i>European Journal of Pharmacology</i> , 2009, 623, 125-131.	1.7	32

#	ARTICLE	IF	CITATIONS
73	Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. <i>International Journal of Clinical Practice</i> , 2010, 64, 756-762.	0.8	32
74	Correlation between arthroscopic and histopathological grading systems of articular cartilage lesions in knee osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2009, 17, 205-212.	0.6	31
75	An OA phenotype may obtain major benefit from bone-acting agents. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 421-428.	1.6	31
76	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty. <i>Drugs and Aging</i> , 2015, 32, 525-535.	1.3	31
77	Dynamic ultrasound assessment of medial meniscal subluxation in knee osteoarthritis. <i>Rheumatology</i> , 2013, 52, 1443-1447.	0.9	30
78	Selective estrogen receptor modulators (SERMs): New alternatives for osteoarthritis?. <i>Maturitas</i> , 2014, 77, 380-384.	1.0	30
79	Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 261-267.	0.5	30
80	Fibrin generated in the synovial fluid activates intimal cells from their apical surface: a sequential morphological study in antigen-induced arthritis. <i>British Journal of Rheumatology</i> , 2003, 42, 19-25.	2.5	28
81	Abatacept Mechanism of Action: Concordance With Its Clinical Profile. <i>Reumatología Clínica (English)</i> Tj ETQq1 10,784314,rgBT/O	0.2	28
82	O-linked N-acetylglucosamine (O-GlcNAc) protein modification is increased in the cartilage of patients with knee osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2014, 22, 259-263.	0.6	28
83	PTH Increases Jaw Mineral Density in a Rabbit Model of Osteoporosis. <i>Journal of Dental Research</i> , 2010, 89, 360-365.	2.5	27
84	Hypercholesterolemia boosts joint destruction in chronic arthritis. An experimental model aggravated by foam macrophage infiltration. <i>Arthritis Research and Therapy</i> , 2013, 15, R81.	1.6	27
85	Chronic arthritis aggravates vascular lesions in rabbits with atherosclerosis: A novel model of atherosclerosis associated with chronic inflammation. <i>Arthritis and Rheumatism</i> , 2008, 58, 2723-2734.	6.7	26
86	Effects of estrogen deficiency and low bone mineral density on healthy knee cartilage in rabbits. <i>Journal of Orthopaedic Research</i> , 2010, 28, 812-818.	1.2	26
87	Targeting subchondral bone in osteoporotic osteoarthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, 494.	1.6	26
88	Tenofovir Causes Bone Loss via Decreased Bone Formation and Increased Bone Resorption, Which Can Be Counteracted by Dipyridamole in Mice. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 923-938.	3.1	26
89	Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities. <i>BMC Research Notes</i> , 2013, 6, 115.	0.6	25
90	The adipokine lipocalin-2 in the context of the osteoarthritic osteochondral junction. <i>Scientific Reports</i> , 2016, 6, 29243.	1.6	25

#	ARTICLE	IF	CITATIONS
91	Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 1-8.	1.6	25
92	Description of a new family with cryopyrin-associated periodic syndrome: risk of visual loss in patients bearing the R260W mutation. <i>Rheumatology</i> , 2014, 53, 1095-1099.	0.9	24
93	Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy. <i>Nature Communications</i> , 2019, 10, 797.	5.8	24
94	Prevalence of spondyloarthritis in Terceira, Azores: a population based study. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 551-553.	0.5	23
95	Compensatory anabolic signaling in the sarcopenia of experimental chronic arthritis. <i>Scientific Reports</i> , 2017, 7, 6311.	1.6	23
96	Parathyroid hormone-related protein exhibits antioxidant features in osteoblastic cells through its N-terminal and osteostatin domains. <i>Bone and Joint Research</i> , 2018, 7, 58-68.	1.3	23
97	Tenidap decreases IL-8 and monocyte chemoattractant peptide-1 (MCP-1) mRNA expression in the synovial tissue of rabbits with antigen arthritis and in cultured synovial cells. <i>Clinical and Experimental Immunology</i> , 1998, 111, 588-596.	1.1	22
98	Effects of PTH [1-34] on synoviopathy in an experimental model of osteoarthritis preceded by osteoporosis. <i>Osteoarthritis and Cartilage</i> , 2012, 20, 1619-1630.	0.6	22
99	Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. <i>Current Medical Research and Opinion</i> , 2015, 31, 1041-1045.	0.9	22
100	The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology. <i>Rheumatology International</i> , 2017, 37, 1227-1236.	1.5	22
101	Meniscal degeneration in human knee osteoarthritis: in situ hybridization and immunohistochemistry study. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2016, 136, 175-183.	1.3	21
102	The combined therapy with chondroitin sulfate plus glucosamine sulfate or chondroitin sulfate plus glucosamine hydrochloride does not improve joint damage in an experimental model of knee osteoarthritis in rabbits. <i>European Journal of Pharmacology</i> , 2017, 794, 8-14.	1.7	21
103	Unexpected Bone Formation Produced by RANKL Blockade. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 695-704.	3.1	20
104	Ultrasound salivary gland involvement in Sjogren's syndrome vs. other connective tissue diseases: is it autoantibody and gland dependent?. <i>Clinical Rheumatology</i> , 2020, 39, 1207-1215.	1.0	20
105	Selective IgA deficiency and spondyloarthropathy: a distinct disease?. <i>Annals of the Rheumatic Diseases</i> , 1990, 49, 636-637.	0.5	19
106	Cartilage and bone biological markers in the synovial fluid of osteoarthritic patients after hyaluronan injections in the knee. <i>Clinica Chimica Acta</i> , 2001, 308, 107-115.	0.5	19
107	Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control. <i>Current Medical Research and Opinion</i> , 2004, 20, 1967-1977.	0.9	19
108	Involvement of platelet-activating factor and tumour necrosis factor in the pathogenesis of joint inflammation in rabbits. <i>Clinical and Experimental Immunology</i> , 2008, 88, 318-323.	1.1	19

#	ARTICLE	IF	CITATIONS
109	Chondrocyte enlargement is a marker of osteoarthritis severity. <i>Osteoarthritis and Cartilage</i> , 2019, 27, 1229-1234.	0.6	19
110	Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis. <i>Journal of Lipid Mediators and Cell Signalling</i> , 1996, 13, 35-49.	1.0	18
111	Endothelin-1 induces loss of proteoglycans and enhances fibronectin and collagen production in cultured rabbit synovial cells. <i>European Journal of Pharmacology</i> , 1996, 302, 191-197.	1.7	18
112	Biochemical markers of bone remodeling and bone sialoprotein in ankylosing spondylitis. <i>Clinica Chimica Acta</i> , 1999, 289, 99-110.	0.5	18
113	Sequential changes of parathyroid hormone related protein (PTHrP) in articular cartilage during progression of inflammatory and degenerative arthritis. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 917-922.	0.5	18
114	Chondroitin sulfate improves synovitis in rabbits with chronic antigen-induced arthritis. <i>Osteoarthritis and Cartilage</i> , 2010, 18, S17-S23.	0.6	18
115	Arthritis in beta-thalassemia minor. <i>Arthritis and Rheumatism</i> , 1983, 26, 1292-1293.	6.7	16
116	Prostaglandin E2 receptors EP1 and EP4 are up-regulated in rabbit chondrocytes by IL-1 $\beta$ , but not by TNF $\alpha$ . <i>Rheumatology International</i> , 2007, 27, 911-917.	1.5	16
117	Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1261-1263.	0.5	16
118	Lack of Association with Rheumatoid Arthritis of Selected Polymorphisms in 4 Candidate Genes: CFH, CD209, Eotaxin-3, and MHC2TA. <i>Journal of Rheumatology</i> , 2009, 36, 1590-1595.	1.0	15
119	Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Drugs and Aging</i> , 2019, 36, 145-159.	1.3	15
120	IL-1 $\beta$ and IL-6 stimulate the production of platelet-activating factor (PAF) cultured rabbit synovial cells. <i>Clinical and Experimental Immunology</i> , 2008, 99, 364-368.	1.1	14
121	Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits. <i>British Journal of Pharmacology</i> , 2010, 161, 1012-1022.	2.7	14
122	Disorganization of chondrocyte columns in the growth plate does not aggravate experimental osteoarthritis in mice. <i>Scientific Reports</i> , 2020, 10, 10745.	1.6	14
123	SAMe restores the changes in the proliferation and in the synthesis of fibronectin and proteoglycans induced by tumour necrosis factor alpha on cultured rabbit synovial cells. <i>Rheumatology</i> , 1997, 36, 27-31.	0.9	13
124	Cyclosporin A prevents the histologic damage of antigen arthritis without inducing fibrosis. <i>Arthritis and Rheumatism</i> , 2000, 43, 311.	6.7	13
125	Transdermal fentanyl for the treatment of pain caused by rheumatoid arthritis. <i>Rheumatology International</i> , 2004, 24, 325-332.	1.5	13
126	Update on the use of abatacept for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 599-621.	1.3	13



#	ARTICLE	IF	CITATIONS
127	Setting up distinctive outcome measures for each osteoarthritis phenotype. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093796.	1.2	13
128	Purinergic System Signaling in Metainflammation-Associated Osteoarthritis. <i>Frontiers in Medicine</i> , 2020, 7, 506.	1.2	13
129	Massive pulmonary hemorrhage: fatal complication of systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 1985, 12, 186-7.	1.0	13
130	An experimental study of COMP (cartilage oligomeric matrix protein) in the rabbit menisci. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2011, 131, 1167-1176.	1.3	12
131	Beneficial effect of fibronectin administration on chronic nephritis in rats. <i>Arthritis and Rheumatism</i> , 1990, 33, 685-692.	6.7	11
132	No Xenotropic Murine Leukemia Virus-related Virus Detected in Fibromyalgia Patients. <i>Emerging Infectious Diseases</i> , 2011, 17, 314-315.	2.0	11
133	DXA in the assessment of subchondral bone mineral density in knee osteoarthritis: A semi-standardized protocol after systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 275-283.	1.6	11
134	Inhibition of pSTAT1 by tofacitinib accounts for the early improvement of experimental chronic synovitis. <i>Journal of Inflammation</i> , 2019, 16, 2.	1.5	11
135	Modulation of the Inflammatory Process by Hypercholesterolemia in Osteoarthritis. <i>Frontiers in Medicine</i> , 2020, 7, 566250.	1.2	11
136	Differences between radiographic abnormalities of acromegalic arthropathy and those of osteoarthritis. <i>Arthritis and Rheumatism</i> , 1990, 33, 455-456.	6.7	10
137	Cartilage oligomeric matrix protein (COMP) is modified by intra-articular liposomal clodronate in an experimental model of arthritis. <i>Clinical and Experimental Rheumatology</i> , 2006, 24, 622-8.	0.4	9
138	Antifibroproliferative effect of tenidap in chronic antigen-induced arthritis. <i>Arthritis and Rheumatism</i> , 1997, 40, 2147-2156.	6.7	8
139	Expression of the peptide C4b-binding protein A in the arthritic joint. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1279-1285.	0.5	8
140	The reverse glucosamine sulfate pathway: application in knee osteoarthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 215-225.	0.9	8
141	Improvement of experimental accelerated atherosclerosis by chondroitin sulphate. <i>Osteoarthritis and Cartilage</i> , 2010, 18, S12-S16.	0.6	8
142	6- <i>Shogaol</i> (enexasogol) treatment improves experimental knee osteoarthritis exerting a pleiotropic effect over immune innate signalling responses in chondrocytes. <i>British Journal of Pharmacology</i> , 2022, 179, 5089-5108.	2.7	8
143	LIMITED FORMS OF WEGENER'S GRANULOMATOSIS PRESENTING AS POLYMYALGIA RHEUMATICA. <i>Rheumatology</i> , 1991, 30, 382-384.	0.9	7
144	Is lecturing in Rheumatology Satellite Symposia a male attribute?. <i>Rheumatology International</i> , 2014, 34, 287-288.	1.5	7

#	ARTICLE	IF	CITATIONS
145	Elevated Plasma Fibronectin Levels in Rats with Immune and Toxic Glomerular Diseases. <i>Renal Failure</i> , 1990, 12, 227-232.	0.8	6
146	Aromatase expression in human chondrocytes: An induction due to culture. <i>Maturitas</i> , 2016, 85, 27-33.	1.0	6
147	Pulmonary Hemorrhage in Lupus Erythematosus Without Evidence of an Immunologic Cause. <i>Archives of Internal Medicine</i> , 1985, 145, 2128.	4.3	5
148	Does oral glucosamine prevent subchondral bone loss in an animal model of osteoarthritis? Comment on the article by Wang et al. <i>Arthritis and Rheumatism</i> , 2008, 58, 635-635.	6.7	5
149	Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: caseâ€“control study. <i>Arthritis Research and Therapy</i> , 2014, 16, 436.	1.6	5
150	Defective function of the mononuclear phagocytic system in rats with chronic nephritis. Evidence of a decreased degradation of IgG aggregates by Kupffer cells. <i>Immunology</i> , 1988, 63, 87-92.	2.0	5
151	Postsalmonella reactive phenomena in 2 patients with ankylosing spondylitis: no modification of the underlying disease. <i>Journal of Rheumatology</i> , 1990, 17, 250-1.	1.0	5
152	Blocking chondrocyte hypertrophy in conditional <i>Evc</i> knockout mice does not modify cartilage damage in osteoarthritis. <i>FASEB Journal</i> , 2022, 36, e22258.	0.2	5
153	Studies of Piroxicam Absorption by Oral Mucosa. <i>Arzneimittelforschung</i> , 2002, 52, 385-387.	0.5	4
154	Glucosamine sulfate for knee osteoarthritis: science and evidence-based use. <i>Therapy: Open Access in Clinical Medicine</i> , 2010, 7, 591-604.	0.2	4
155	Randomized clinical trials as reflexiveâ€“interpretative process in patients with rheumatoid arthritis: a qualitative study. <i>Rheumatology International</i> , 2015, 35, 1423-1430.	1.5	4
156	Validation of Musculoskeletal Ultrasound in the Assessment of Experimental Gout Synovitis. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 1516-1524.	0.7	4
157	Treating osteoporotic osteoarthritis, or the art of cutting a balding man's hair. <i>Osteoarthritis and Cartilage</i> , 2020, 28, 239-241.	0.6	4
158	Adenosine Deaminase as a Biomarker of Tenofovir Mediated Inflammation in Naïve HIV Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3590.	1.8	4
159	Use of crystalline glucosamine sulfate in osteoarthritis. <i>Future Rheumatology</i> , 2006, 1, 397-414.	0.2	3
160	Subchondral bone remodelling and osteoarthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, .	1.6	3
161	Chondroitin sulfate â€” CONCEPT clear, uncertainties unchanged. <i>Nature Reviews Rheumatology</i> , 2017, 13, 576-577.	3.5	3
162	Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11490.	1.8	3

#	ARTICLE	IF	CITATIONS
163	PAF, a potent proinflammatory mediator, looking for its role in the pathogenesis of joint damage. <i>Annals of the Rheumatic Diseases</i> , 1997, 56, 211-213.	0.5	2
164	HLA-B27 in patients with a permanent pacemaker. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 1018-1018.	0.5	2
165	244 OSTEOARTHRITIS LEADS TO INCREASED LEVELS OF PROTEIN O-LINKED N-ACETYLGLUCOSAMINE IN THE CARTILAGE. <i>Osteoarthritis and Cartilage</i> , 2010, 18, S111-S112.	0.6	2
166	Study of the O-linked-N-acetyl-glucosaminylation of proteins induced by high doses of glucosamine and its correlation with osteoarthritis progression. <i>Osteoarthritis and Cartilage</i> , 2012, 20, S126.	0.6	2
167	<p>It Is the Time to Think About a Treat-to-Target Strategy for Knee Osteoarthritis</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 1479-1482.	0.9	2
168	Joint obesity as a pathogenic factor in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2021, 29, 1239-1241.	0.6	2
169	Pulmonary infiltrates and abdominal colic pain in a patient with a connective tissue disorder. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 15-19.	0.5	1
170	Viscosupplementation for Osteoarthritis of the Knee. <i>Annals of Internal Medicine</i> , 2013, 158, 74.	2.0	1
171	Estrogen-Dependent Transcriptional Activity: A Protection Against ROS in Osteoarthritis. , 2013, , 369-391.		1
172	References from the classical rheumatologic literature. <i>Arthritis and Rheumatism</i> , 1985, 28, 1320-1320.	6.7	0
173	Protein-losing enteropathy caused by systemic lupus erythematosus. <i>Gut</i> , 1985, 26, 757-758.	6.1	0
174	Grado de conocimiento de la osteoporosis en mujeres posmenopáusicas. <i>Revista Española De Enfermedades Metabólicas Áreas</i> , 2008, 17, 71-75.	0.0	0
175	Do Clinical Practice Guidelines Do Enough to Help Clinicians Identify Patients at High Risk of Osteoporotic Fracture?. <i>Journal of Clinical Rheumatology</i> , 2011, 17, S57.	0.5	0
176	¿Osteoimmunología, osteo-reumatología o reumatología sin más?. <i>Reumatología Clínica</i> , 2013, 9, 257-258.	0.2	0
177	Reply. <i>Arthritis and Rheumatology</i> , 2017, 69, 2093-2094.	2.9	0
178	Does anti-tumour necrosis factor alpha therapy exert a long-term structural benefit in hand osteoarthritis?. <i>Rheumatology</i> , 2018, 57, 1879-1880.	0.9	0
179	Response to: â€œCorrespondence on â€œGlucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?â€™ by Angelides and Manolios. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2020-219721.	0.5	0